| scholarly article | Q13442814 |
| P50 | author | Todd D Gould | Q59826938 |
| Panos Zanos | Q85283572 | ||
| P2093 | author name string | Craig J Thomas | |
| Carlos A Zarate | |||
| Ruin Moaddel | |||
| Amy Q Wang | |||
| Jaclyn N Highland | |||
| Jacqueline Lovett | |||
| Patrick J Morris | |||
| Soumita Ghosh | |||
| P2860 | cites work | Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. | Q47447132 |
| Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects. | Q47570724 | ||
| Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression | Q47817664 | ||
| Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine | Q48279921 | ||
| Stereochemical and structural effects of (2R,6R)-hydroxynorketamine on the mitochondrial metabolome in PC-12 cells. | Q51764248 | ||
| Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. | Q51861327 | ||
| Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations. | Q51864897 | ||
| Pharmacokinetics and analgesic effects of i.m. and oral ketamine | Q51866378 | ||
| Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. | Q52604451 | ||
| Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. | Q55438088 | ||
| NMDAR-independent, cAMP-dependent antidepressant actions of ketamine. | Q55456849 | ||
| Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants | Q57293270 | ||
| Physiological parameters in laboratory animals and humans | Q72935917 | ||
| (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray | Q89313902 | ||
| Efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain | Q91035496 | ||
| NPHP4 is necessary for normal photoreceptor ribbon synapse maintenance and outer segment formation, and for sperm development | Q28586324 | ||
| Antidepressant effects of ketamine in depressed patients | Q29617327 | ||
| A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression | Q29617914 | ||
| mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists | Q29618120 | ||
| Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses | Q29618915 | ||
| NMDAR inhibition-independent antidepressant actions of ketamine metabolites. | Q30370600 | ||
| NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses | Q30471587 | ||
| Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects | Q30841490 | ||
| Switch over from intravenous to oral therapy: A concise overview | Q33561813 | ||
| (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function. | Q33770827 | ||
| Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression | Q33956313 | ||
| A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome | Q34166221 | ||
| A randomized controlled trial of intranasal ketamine in major depressive disorder | Q34288196 | ||
| Prodrugs: a challenge for the drug development | Q34337609 | ||
| Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder | Q34451408 | ||
| The STAR*D trial: revealing the need for better treatments | Q34613368 | ||
| The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats | Q35822283 | ||
| Ketamine Metabolites Enantioselectively Decrease Intracellular D-Serine Concentrations in PC-12 Cells | Q35994750 | ||
| Stereoselective and regiospecific hydroxylation of ketamine and norketamine | Q36186055 | ||
| Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression | Q36233963 | ||
| Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. | Q36501166 | ||
| Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters. | Q37279054 | ||
| Amino acids as promoieties in prodrug design and development | Q38055644 | ||
| A REVIEW OF KETAMINE ABUSE AND DIVERSION. | Q38872263 | ||
| Recent progress in prodrug design strategies based on generally applicable modifications | Q39175011 | ||
| Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats. | Q39887388 | ||
| Biotransformation and Disposition of Ketamine | Q39943969 | ||
| Measurement of rodent stereotyped behavior | Q42168114 | ||
| Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. | Q42253330 | ||
| What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression | Q43251150 | ||
| Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers | Q44271215 | ||
| Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression | Q44647972 | ||
| Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study | Q46051442 | ||
| Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (E)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations | Q46247353 | ||
| Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit | Q47306135 | ||
| Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling | Q47380939 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bioavailability | Q461809 |
| P304 | page(s) | 269881118812095 | |
| P577 | publication date | 2018-11-29 | |
| P1433 | published in | Journal of Psychopharmacology | Q6295819 |
| P1476 | title | Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( 2R,6R)-hydroxynorketamine |
| Q92339977 | (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions |
| Q91843765 | Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function |
| Q92873306 | Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective |
Search more.